Eventide Asset Management LLC Has $14.37 Million Position in Kymera Therapeutics, Inc. $KYMR

Key Points

• Eventide Asset Management LLC increased its stake in Kymera Therapeutics by 15.2%, now owning approximately 0.81% of the company valued at around $14.37 million.
• Kymera Therapeutics recently missed its earnings estimate for the quarter, reporting a loss of ($0.95) earnings per share and a revenue of $11.48 million.
• Analysts show mixed perspectives on Kymera Therapeutics, with ratings ranging from a "buy" to "sell," and a consensus rating currently at "buy" with an average price target of $58.76.

Eventide Asset Management LLC boosted its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 15.2% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 525,138 shares of the company's stock after buying an additional 69,410 shares during the period. Eventide Asset Management LLC owned approximately 0.81% of Kymera Therapeutics worth $14,373,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Northern Trust Corp raised its holdings in Kymera Therapeutics by 14.0% in the fourth quarter. Northern Trust Corp now owns 437,833 shares of the company's stock valued at $17,614,000 after buying an additional 53,658 shares during the period. Ameriprise Financial Inc. purchased a new position in Kymera Therapeutics in the fourth quarter valued at approximately $344,000. GAMMA Investing LLC grew its position in Kymera Therapeutics by 3,851.5% in the first quarter. GAMMA Investing LLC now owns 6,678 shares of the company's stock valued at $183,000 after acquiring an additional 6,509 shares in the last quarter. Millennium Management LLC grew its position in Kymera Therapeutics by 205.0% in the fourth quarter. Millennium Management LLC now owns 115,918 shares of the company's stock valued at $4,663,000 after acquiring an additional 77,912 shares in the last quarter. Finally, Rhumbline Advisers grew its position in Kymera Therapeutics by 9.0% in the first quarter. Rhumbline Advisers now owns 69,928 shares of the company's stock valued at $1,914,000 after acquiring an additional 5,771 shares in the last quarter.

Kymera Therapeutics Stock Up 2.1%

Kymera Therapeutics stock traded up $0.91 during midday trading on Tuesday, hitting $44.17. The company's stock had a trading volume of 189,230 shares, compared to its average volume of 735,977. The company has a market capitalization of $3.16 billion, a PE ratio of -12.73 and a beta of 2.17. The stock's 50-day moving average price is $43.37 and its 200-day moving average price is $37.03. Kymera Therapeutics, Inc. has a 12 month low of $19.44 and a 12 month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The firm had revenue of $11.48 million during the quarter, compared to the consensus estimate of $17.37 million. Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The company's quarterly revenue was down 55.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.58) EPS. As a group, equities analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Buying and Selling

In other news, Director Bvf Partners L. P/Il bought 317,167 shares of the business's stock in a transaction that occurred on Monday, June 30th. The stock was acquired at an average cost of $44.00 per share, for a total transaction of $13,955,348.00. Following the completion of the purchase, the director owned 2,798,795 shares of the company's stock, valued at $123,146,980. This trade represents a 12.78% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bros. Advisors Lp Baker bought 655,500 shares of the business's stock in a transaction that occurred on Monday, June 30th. The stock was purchased at an average price of $44.00 per share, with a total value of $28,842,000.00. Following the completion of the purchase, the director directly owned 6,117,295 shares of the company's stock, valued at $269,160,980. This represents a 12.00% increase in their position. The disclosure for this purchase can be found here. 16.01% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. JPMorgan Chase & Co. increased their price objective on shares of Kymera Therapeutics from $57.00 to $64.00 and gave the company an "overweight" rating in a research report on Tuesday, June 3rd. UBS Group reduced their price objective on shares of Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Wells Fargo & Company reduced their price objective on shares of Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating for the company in a report on Thursday, June 26th. The Goldman Sachs Group raised shares of Kymera Therapeutics to a "strong-buy" rating in a report on Tuesday, July 15th. Finally, Stifel Nicolaus assumed coverage on shares of Kymera Therapeutics in a report on Tuesday, May 20th. They issued a "buy" rating and a $55.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, Kymera Therapeutics has an average rating of "Buy" and an average price target of $58.76.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.